Synlogic (SYBX) Stock Price, News & Analysis

Company Overview

Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618, an orally administered, non-systemically absorbed drug candidate to treat phenylketonuria; SYNB1934, an orally administered, non-systemically absorbed drug candidate, which is in Phase III clinical trial to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase II clinical trial for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. for the research and pre-clinical development of a synthetic biotic medicine for the treatment of inflammatory bowel disease; and Ginkgo Bioworks, Inc. Synlogic, Inc. is based in Cambridge, Massachusetts.

Key Stats

• Today's Range: $1.64 to $1.78
• 50-Day Range: $1.40 to $1.83
• 52-Week Range: $0.90 to $1.96
• Volume: 16,077 shs
• Average Volume: 35,329 shs
• Market Capitalization: $20.12 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

SYBX Stock Analysis - Frequently Asked Questions

How have SYBX shares performed this year?

Synlogic's stock was trading at $1.40 at the beginning of the year. Since then, SYBX stock has increased by 22.9% and is now trading at $1.72.

How were Synlogic's earnings last quarter?

Synlogic, Inc. (NASDAQ:SYBX) posted its earnings results on Thursday, March, 6th. The biotechnology company reported ($0.06) earnings per share for the quarter, beating analysts' consensus estimates of ($0.10) by $0.04.

When did Synlogic's stock split?

Synlogic's stock reverse split before market open on Thursday, September 28th 2023.The 1-15 reverse split was announced on Thursday, September 28th 2023. The number of shares owned by shareholders was adjusted after the market closes on Thursday, September 28th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

How do I buy shares of Synlogic?

Shares of SYBX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Synlogic own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Synlogic investors own include Reata Pharmaceuticals (RETA), Sangamo Therapeutics (SGMO), Approach Resources (AREX), Precision Drilling (PDS), First Financial Bankshares (FFIN), Sorrento Therapeutics (SRNE) and Exelixis (EXEL).

Company Calendar

• Last Earnings: 3/06/2025
• Today: 10/24/2025
• Next Earnings (Estimated): 11/11/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:SYBX
• CIK: 1527599
• Web: www.synlogictx.com
• Phone: (617) 401-9975
• Fax: 512-681-5201
• Employees: 80
• Year Founded: 2013

Profitability

• EPS (Trailing Twelve Months): ($0.08)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$23.36 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -8.09%
• Return on Assets: -5.50%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.63
• Quick Ratio: 3.63

Sales & Book Value

• Annual Sales: $10 thousand
• Price / Sales: 2,012.40
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.09 per share
• Price / Book: 1.58

Miscellaneous

• Outstanding Shares: 11,700,000
• Free Float: 11,346,000
• Market Cap: $20.12 million
• Optionable: Optionable
• Beta: 0.55